FLOT Plus Durvalumab Leads to High pCR Rate in Gastric Cancer
Durvalumab + 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) resulted in a higher pathological complete response (pCR) rate than FLOT alone.
FLOT Plus Durvalumab Leads to High pCR Rate in Gastric Cancer
Durvalumab + 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) resulted in a higher pathological complete response (pCR) rate than FLOT alone.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
